An Update on a Few of the Stories we are Tracking – OPMG, BMGP, BIEL, TZPC, PASO, APNN, MDHI
There is certainly a lot going on with several of the companies we are tracking. Here’s a brief summary.
Options Media Group (OPMG) – This is the stock we feel investors should be watching most closely. Based on what we think is coming up, we think these shares are a steal at current levels. The Company recently announced it had finalized the acquisition of PhoneGuard, which holds the North American rights to the number one market share smart phone anti-virus software in the world. OPMG will also be introducing a revolutionary new product to the market that when loaded onto cell or smartphones will lock the keyboard when the handset is traveling at a rate faster than ten miles per hour. This “anti-texting while driving” software could be a huge hit. Cell and smart phone viruses in Asia and Europe are prevalent and will soon become a major issue here in the U.S. – and of course, we all know how much pressure is building against text while driving. Look for major new revenue producing initiative centering on these new products over the short term. Balance sheet is clean with good cash and no long term debt. OPMG shares should be strongly considered. Clearly, our favorite name short term.
Biomagnetics Diagnostics (BMGP) – CEO Hardman should be back from his long trip to India and Thailand where he met with health ministries and clinical trial partners. He has secured trial partners for both malaria and TB. Last week, the World Health Organization issued new guidelines that call for all suspected malaria patients to be tested prior to medication being administered. Currently, most clinics simply dose patients with malaria drugs first, since testing is often too expensive or not available at all. This is costing a fortune in anti-malaria drugs and causing shortages. The directive will likely cause many agencies to be more aggressive in the search for better diagnostic tools. Look for an additional Los Alamos agreement out of BMGP over the short term and for the Company to gear up demonstrations of the IOBS unit now that they have received the first unit for the lab. With only 64 mm shares outstanding, I think these shares are a steal. TB version should be out in August, which will also believe to be a major revenue opportunity.
Bioelectronics (BIEL) – I am just now wrapping up a long trip to Asia meeting with distribution partners for Bioelectronics and YesDTC products (I am the CEO of YesDTC for anyone who is unaware). Very strong interest in the Allay product out of distributors based in Hong Kong who want to take the product throughout Asia. Additionally, we are moving aggressively toward a regulatory filing for Japan, where it appears we will be classified as a Class I device – really good news for both BIEL and YESD. BIEL has now launched the Canadian DRTV spots and we should have data over the next few days. Recent additional conversations have taken place with FDA on the Allay and ActiPatch 510Ks. Both are still very much alive and Andy Whelan is indicating a full update to investors will likely be made available over the short term. It is good to see the process with the FDA still pushing forward. The new consultant helping with the process has provided valuable additional insight for the management team. Andy Whelan will be starting a brokerage road show early next week designed to both generate interest in the Company and to accelerate the 211C process for movement to OTC.
ThermaFreeze Products Corp (TZPC) – The retail rollout continues at a rapid pace. We have received lots of photos from the Company and from investors showing the products on the shelves of many stores. Most of these are East coast based. Look for rapid expansion west of the Mississippi over the coming weeks. Early store data looks encouraging. If you want a free sample of this innovative product, send me an email and we will send you some. Let’s all hope for a blazing hot spring and summer to drive ThermaFreeze product sales. Company clearly moving from development stage to revenue production stage.
Patient Access Solutions (PASO) – I poke fun at Bruce Weitzberg, CEO of PASO, every once in awhile because a few months ago when I would call him, he would answer the call on the first ring. Now I have to leave him a message because he says he is so busy with potential customers. PASO is starting to make headway selling both EMR and especially, its home health care targeted digital pen solution. We have been waiting for this revenue stream to begin, which now appears to be right around the corner.
Applied Nanosciene (APNN) – APNN is a bit of a shy company – however – investors who are willing to do homework should analyze this Company closely. The Company has a nanoparticle facial mask that is revolutionary. The Company has now been able to spray the solution onto mask material with actual production and revenue generation likely during Q2. If APNN can pull this off, it will be a great revenue stream. If all this sounds confusing, listen to the CEO interview here on the blog. This is an interesting technology and Company. Once revenue production begins, these shares should be aggressively purchased.
Medical Alarm Concepts (MDHI) – After a robust start to trading, shares have moved significantly lower as the Company has run low on funds to begin the major portion of its marketing programs. A new group of investors is likely to come to the rescue over the short term to provide these need funds. This product is unique in that it is the only personal medical alarm product that allows the owner to speak with emergency personnel directly through the pendant that is worn around the neck. For this reason, we continue to like this story. If they get the additional funding, which I believe they will, these shares should recover quickly and strongly. I am considering funding part of the required funds out of my own pocket. Stay tuned to this developing story.
